Leucid Bio

Leucid Bio Ltd is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for hard-to-treat solid tumours.

Founded on over two decades of King's College London research, the platform redesigns the CAR signalling architecture to enhance T-cell potency, persistence, and tumour infiltration.

Lead asset LEU011 targets NKG2D stress ligands expressed on over 80% of human tumours and is being evaluated in the Phase I/IIa AERIAL multi-centre dose-escalation trial, manufactured at Great Ormond Street Hospital's GMP facilities.